FDMT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FDMT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. 4D Molecular Therapeutics's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.
Accounts receivable can be measured by Days Sales Outstanding. 4D Molecular Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 0.00.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. 4D Molecular Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $9.71.
The historical data trend for 4D Molecular Therapeutics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4D Molecular Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Accounts Receivable | Get a 7-Day Free Trial | 0.98 | 1.49 | 0.05 | - | - |
4D Molecular Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Accounts Receivable | Get a 7-Day Free Trial | - | - | - | - | - |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
4D Molecular Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0.028 | * | 91 |
= | 0.00 |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), 4D Molecular Therapeutics's accounts receivable are only considered to be worth 75% of book value:
4D Molecular Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (525.911 | + | 0.75 * 0 | + | 0.5 * 0 | - | 29.323 |
- | 0 | - | 0) | / | 51.1574 | ||
= | 9.71 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of 4D Molecular Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
David Kirn | director, officer: Chief Executive Officer | C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Uneek Mehra | officer: See Remarks | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Rose Sharon Shabet | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Parent Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Ole Andreas Halvorsen | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
David C. Ott | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Portfolio Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Gp Llc | 10 percent owner | 55 RAILROAD AVENUE, GREENWICH CT 06830 |
Viking Global Opportunities Illiquid Investments Sub-master Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Jacob Chacko | director | C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121 |
Scott Bizily | officer: Chief Legal and HR Officer | C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608 |
Robert Young Kim | officer: Chief Medical Officer | C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608 |
Noriyuki Kasahara | director | C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608 |
Bvf I Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By sperokesalga sperokesalga • 02-16-2023
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 07-29-2023
By sperokesalga sperokesalga • 05-04-2023
By sperokesalga sperokesalga • 05-10-2023
By Marketwired • 07-17-2023
By Marketwired • 09-07-2023
By Marketwired • 10-23-2023
By sperokesalga sperokesalga • 05-24-2023
By GuruFocus Research GuruFocus Editor • 01-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.